Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
45
pubmed:dateCreated
2005-11-10
pubmed:abstractText
DYT1 is the most common inherited dystonia. Currently, there are no preventive or curative therapies for this dominantly inherited disease. DYT1 dystonia is caused by a common three-nucleotide deletion in the TOR1A gene that eliminates a glutamic acid residue from the protein torsinA. Recent studies suggest that torsinA carrying the disease-linked mutation, torsinA(DeltaE) acts through a dominant-negative effect by recruiting wild-type torsinA [torsinA(wt)] into oligomeric structures in the nuclear envelope. Therefore, suppressing torsinA(DeltaE) expression through RNA interference (RNAi) could restore the normal function of torsinA(wt), representing a potentially effective therapy regardless of the biological role of torsinA. Here, we have generated short hairpin RNAs (shRNAs) that mediate allele-specific suppression of torsinA(DeltaE) and rescue cells from its dominant-negative effect, restoring the normal distribution of torsinA(wt). In addition, delivery of this shRNA by a recombinant feline immunodeficiency virus effectively silenced torsinA(DeltaE) in a neural model of the disease. We further establish the feasibility of this viral-mediated RNAi approach by demonstrating significant suppression of endogenous torsinA in mammalian neurons. Finally, this silencing of torsinA is achieved without triggering an interferon response. These results support the potential use of viral-mediated RNAi as a therapy for DYT1 dystonia and establish the basis for preclinical testing in animal models of the disease.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1529-2401
pubmed:author
pubmed:issnType
Electronic
pubmed:day
9
pubmed:volume
25
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
10502-9
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:16280588-Animals, pubmed-meshheading:16280588-Blotting, Western, pubmed-meshheading:16280588-Cell Count, pubmed-meshheading:16280588-Cells, Cultured, pubmed-meshheading:16280588-Cercopithecus aethiops, pubmed-meshheading:16280588-Cerebral Cortex, pubmed-meshheading:16280588-Ciprofloxacin, pubmed-meshheading:16280588-Cloning, Molecular, pubmed-meshheading:16280588-Doxycycline, pubmed-meshheading:16280588-Dystonia, pubmed-meshheading:16280588-Embryo, Mammalian, pubmed-meshheading:16280588-Fluorescent Antibody Technique, pubmed-meshheading:16280588-Gene Expression Regulation, pubmed-meshheading:16280588-Gene Silencing, pubmed-meshheading:16280588-Green Fluorescent Proteins, pubmed-meshheading:16280588-Humans, pubmed-meshheading:16280588-Interferons, pubmed-meshheading:16280588-Lentivirus, pubmed-meshheading:16280588-Mice, pubmed-meshheading:16280588-Molecular Chaperones, pubmed-meshheading:16280588-Mutagenesis, pubmed-meshheading:16280588-Neurons, pubmed-meshheading:16280588-Organotechnetium Compounds, pubmed-meshheading:16280588-RNA, Small Interfering, pubmed-meshheading:16280588-Sequence Deletion, pubmed-meshheading:16280588-Transfection
pubmed:year
2005
pubmed:articleTitle
Silencing primary dystonia: lentiviral-mediated RNA interference therapy for DYT1 dystonia.
pubmed:affiliation
Department of Neurology, Carver College of Medicine, University of Iowa, Iowa City, Iowa 52242, USA. pedro-gonzalez-alegre@uiowa.edu
pubmed:publicationType
Journal Article, Comparative Study, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural